Acute leukemia is divided into acute myeloid leukemia and acute lymphoblastic leukemia, and the chemotherapy regimens for these two leukemias are different. First, for acute myeloid leukemia, the commonly used chemotherapy regimen is the 3+7 regimen, where the 3 refers to the application of anthracycline chemotherapy drugs for 3 days. These drugs include roxithromycin, desoxorubicin, mitoxantrone, etc. The 7 therein refers to the fact that agranulocytosis should be applied for 7 consecutive days, hence the name 3+7 regimen. In addition to the 3+7 regimen, acute myeloid leukemia can also be treated with three-drug combination chemotherapy, such as adding high trichostatin to erythromycin plus cytarabine to form a HAD regimen, and also applying medium to high doses of cytarabine for single-drug chemotherapy. The chemotherapy used in acute lymphoblastic leukemia is usually a multidrug combination chemotherapy, for example, the induction chemotherapy regimen VDCLP applying a combination of five chemotherapeutic agents, and most of the chemotherapy regimens contain vincristine, glucocorticoids, and menadionease. In addition to multidrug combination chemotherapy, acute lymphoblastic leukemia is usually treated with high-dose methotrexate, which is characterized by high-dose methotrexate penetrating into the central nervous system or reproductive system to effectively kill leukemic cells in these areas and prevent disease recurrence.